October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
August 1, 2024 Advancing Rare Disease Measurement With The Rare Disease COA Resource It is estimated that more than 350 million people worldwide live with a rare disease.
April 24, 2024 COA Program Concludes Successful Annual Meeting On April 17 and 18, C-Path's Clinical Outcome Assessment (COA) Program hosted its Annual Meeting in Rockville, MD...
May 18, 2018 “Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
May 7, 2018 C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
December 18, 2017 C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS) Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
October 24, 2017 US FDA Awards I-ACT for Children a Grant for Pediatric Medicines and Devices Network
